Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis.

Atherosclerosis. Supplements - 1 Nov 2017

Dlouha Dana, Blaha Milan, Blaha Vladimir, Fatorova Ilona, Hubacek Jaroslav A, Stavek Petr, Lanska Vera, Parikova Alena, Pitha Jan

Abstract excerpt

BACKGROUND: LDL/Lp(a) apheresis therapy is a well-established method of aggressively lowering LDL and Lp(a). Recently, miRNAs have been discussed as markers of vascular status including atherosclerosis. MiRNAs inhibit post-transcriptional processes through RNA duplex formation resulting in gene silencing or regulation of gene expression. MATERIALS AND METHODS: We measured a profile of 175 plasma-circulating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Blood Component Removal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Homozygote

Share to Hyperlipoproteinemia Type II

Share to Lipoprotein(a)

Share to Transcriptome

Share to Treatment Outcome

Source

Identifiers

PMID: 29096828
DOI: 10.1016/j.atherosclerosissup.2017.05.037

Genes

LDLR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis.PMID 29096828Read ↗

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.Semantic proximity Read ↗

The Acute Effects of Lipoprotein Apheresis on Monocyte Subset Distribution and Transcriptome in Patients With and Without Elevated Lipoprotein(a)Semantic proximity Read ↗

Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?Semantic proximity Read ↗

Nucleic Acid–Based Therapies for AtherosclerosisSemantic proximity Read ↗

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.Semantic proximity Read ↗

Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.Semantic proximity Read ↗

‘Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patients’Semantic proximity Read ↗

Treatment of Lp(a): Is It the Future or Are We Ready Today?Semantic proximity Read ↗

Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndromeSemantic proximity Read ↗

Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)Semantic proximity Read ↗

Smoking alters circulating plasma microvesicle pattern and microRNA signaturesSemantic proximity Read ↗

The Expression Levels of Plasma micoRNAs in Atrial Fibrillation PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.